LABORATORIO REIG JOFRE S.A. (ES:RJF)
BME:RJF
Want to see ES:RJF full AI Analyst Report?
RJF Stock Chart & Stats
€2.68
€0.00(0.00%)
At close: 4:00 PM EST
€2.68
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.32 - €3.35
Previous CloseN/A
Volume1.57K
Average Volume (3M)44.99K
Market Cap
€218.06M
Enterprise Value€304.35M
Total Cash (Recent Filing)€10.84M
Total Debt (Recent Filing)€67.06M
Price to Earnings (P/E)49.1
Beta0.30
Next Earnings
Jul 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.91%
Share Statistics
EPS (TTM)0.11
Shares Outstanding82,219,240
10 Day Avg. Volume48,066
30 Day Avg. Volume44,988
Financial Highlights & Ratios
PEG Ratio-0.79
Price to Book (P/B)0.96
Price to Sales (P/S)0.63
P/FCF Ratio-15.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.15
Revenue Forecast (FY)€358.95M
Bulls Say, Bears Say
Bulls Say
Diversified Revenue Model (products + CDMO)A dual business model combining branded/specialty pharmaceuticals and CDMO services provides durable revenue diversification. Contract manufacturing can deliver multi-year supply agreements and capacity utilization cushioning product cyclicalities, supporting steadier cash generation over months to years.
Multi-year Revenue Expansion Prior To 2025A multi-year expansion through 2024 indicates established commercial traction, market access and customer relationships. This historical growth demonstrates structural competitiveness and product adoption that can support recovery if 2025 weakness proves cyclical rather than permanent.
Moderate Historical Leverage And Growing Equity BaseHistorically moderate debt ratios and gradual equity growth provide balance-sheet resilience and financial flexibility. That capital structure gives the company room to fund operations or investments without immediate refinancing stress, aiding stability over the next several quarters.
Bears Say
Sharp 2025 Revenue And Margin DeteriorationA large revenue drop coupled with collapsed margins sharply reduces core earnings power and operating leverage. Such material deterioration can be symptomatic of structural demand loss, pricing pressure, or higher input costs, making recovery and margin restoration uncertain over a 2–6 month horizon.
Negative Free Cash Flow And Weakened Operating Cash FlowA swing to materially negative free cash flow weakens the company's ability to fund capex, repay debt, or support operations internally. This increases reliance on external financing and heightens liquidity risk, especially given volatile historical cash generation, constraining strategic flexibility for months ahead.
Increased Leverage In 2025Rising leverage amid falling earnings and weak cash flow raises solvency and covenant risks. Higher leverage increases interest burden and reduces capacity to invest in growth or absorb shocks, making the company more vulnerable to prolonged operational headwinds over the medium term.
LABORATORIO REIG JOFRE News
RJF FAQ
What was LABORATORIO REIG JOFRE S.A.’s price range in the past 12 months?
LABORATORIO REIG JOFRE S.A. lowest stock price was €2.32 and its highest was €3.35 in the past 12 months.
What is LABORATORIO REIG JOFRE S.A.’s market cap?
LABORATORIO REIG JOFRE S.A.’s market cap is €218.06M.
When is LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date?
LABORATORIO REIG JOFRE S.A.’s upcoming earnings report date is Jul 31, 2026 which is in 44 days.
How were LABORATORIO REIG JOFRE S.A.’s earnings last quarter?
LABORATORIO REIG JOFRE S.A. released its earnings results on May 07, 2026. The company reported €0.038 earnings per share for the quarter, beating the consensus estimate of N/A by €0.038.
Is LABORATORIO REIG JOFRE S.A. overvalued?
According to Wall Street analysts LABORATORIO REIG JOFRE S.A.’s price is currently Overvalued.
Does LABORATORIO REIG JOFRE S.A. pay dividends?
LABORATORIO REIG JOFRE S.A. pays a Annually dividend of €0.019 which represents an annual dividend yield of 1.91%. See more information on LABORATORIO REIG JOFRE S.A. dividends here
What is LABORATORIO REIG JOFRE S.A.’s EPS estimate?
LABORATORIO REIG JOFRE S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LABORATORIO REIG JOFRE S.A. have?
LABORATORIO REIG JOFRE S.A. has 82,219,240 shares outstanding.
What happened to LABORATORIO REIG JOFRE S.A.’s price movement after its last earnings report?
LABORATORIO REIG JOFRE S.A. reported an EPS of €0.038 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.087%.
Which hedge fund is a major shareholder of LABORATORIO REIG JOFRE S.A.?
Currently, no hedge funds are holding shares in ES:RJF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
LABORATORIO REIG JOFRE S.A.
Laboratorio Reig Jofre, S.A. is a pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of a diverse range of medicines and nutritional supplements. Its extensive portfolio encompasses prescription drugs, over-the-counter (OTC) products, medical devices, and cosmetics. The company's offerings are categorized into several key areas: advanced pharmaceutical technologies, which include antibiotics and injectable formulations; specialized healthcare solutions targeting dermatological, musculoskeletal (joint health and pain), women's health, respiratory/ENT, and pediatric needs; and consumer health items marketed under its Forté Pharma brand. Furthermore, Laboratorio Reig Jofre provides contract development and manufacturing (CDMO) as well as contract manufacturing organization (CMO) services. Founded in 1929 and headquartered in Sant Joan Despí, Spain, the company sells its products directly in seven countries and collaborates with business partners to reach approximately 70 other nations. It operates as a subsidiary of Reig Jofre Investments SL.
Technical Analysis
Options Prices
Currently, No data available
---